.avif)
Deciphera Pharmaceuticals Email Format
Pharmaceutical Manufacturing
・
201-500 employees
・
Waltham, MA, USA
Deciphera Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing innovative kinase inhibitor medicines to improve the lives of people with cancer.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
first.last@deciphera.com
Company Overview
Industry
Pharmaceutical Manufacturing
Founded
2003
Headquarters
Waltham, MA, USA
Revenue
$100M+
FUNDING Stage
Public
Website
Key Executives
Ryota Udagawa (President & Chief Executive Officer), Jenn Larson (Senior Vice President and Chief Financial Officer), Margarida Duarte (Executive Vice President, Global Chief Commercial Officer)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Deciphera Pharmaceuticals?
Deciphera Pharmaceuticals uses the first.last format on deciphera.com, so Jane Smith would be jane.smith@deciphera.com.
What approved products does Deciphera Pharmaceuticals currently market?
Deciphera Pharmaceuticals has two FDA-approved products: QINLOCK (ripretinib), a kinase inhibitor for advanced gastrointestinal stromal tumor, and ROMVIMZA (vimseltinib), a CSF1R inhibitor approved in February 2025 for symptomatic tenosynovial giant cell tumor.
Who leads Deciphera Pharmaceuticals as CEO?
Ryota Udagawa serves as President and Chief Executive Officer of Deciphera Pharmaceuticals. Other senior leaders include Chief Financial Officer Jenn Larson and Global Chief Commercial Officer Margarida Duarte.
Where is Deciphera Pharmaceuticals headquartered and how large is the company?
Deciphera Pharmaceuticals is headquartered in Waltham, MA, and has approximately 535 employees. If you need to find a specific contact there, tools like Clay can help you locate and verify individual email addresses.
Does Deciphera Pharmaceuticals have any pipeline programs beyond QINLOCK and ROMVIMZA?
Yes, Deciphera Pharmaceuticals has an active pipeline including inlexisertib (a ULK inhibitor being studied in advanced GIST), DCC-2812, and tirabrutinib (a BTK inhibitor licensed from ONO Pharmaceutical targeting primary central nervous system lymphoma), among other candidates.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating